ICATIBANT®

Firazyr®

FDA INDICATION: Firazyr is a bradykinin B2 receptor antagonist indicated for treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older. Package Insert

FORM: Liquid

DISTRIBUTOR: Shire

ROUTE OF ADMINISTRATION: Subcutaneous (SC)

DOSAGE STRENGTH: 30 mg (10 mg per mL)

DILUENT SIZE: 3 mL (prefilled syringe)

DOSE: 30 mg administered by SC injection in the abdominal area

MIXING DEVICE: Single-use, prefilled syringe

STORAGE: Store between 2–25°C (36–77°F). Do not freeze.

SELF-ADMINISTRATION: Yes, after training

HALF-LIFE: 1.4 ± 0.4 hours

OTHER WEBSITES: discoverHAE.comfirazyr.com